The pharmacotherapy of male hypogonadism besides androgens

Bibliography

• Sertoli E. Dell’ esistenza di particolari cellule ramificate nei canalicoli seminiferi del testicolo umano. Morgagni 1865;7:31-40
   Google Scholar
• Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 2013;10:245-84
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Vignozzi L, et al. How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 2012;14:251-9
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Vignozzi L, Maggi M. Emerging medication for the treatment of male hypogonadism. Expert Opin Emerg Drugs 2012;17:239-59
   PubMed Web of Science ®Google Scholar
• Morelli A, Fibbi B, Marini M, et al. Dihydrotestosterone and leptin regulate gonadotropin-releasing hormone (GnRH) expression and secretion inhuman GnRH-secreting neuroblasts. J Sex Med 2009;6:397-407
   PubMed Web of Science ®Google Scholar
• Young J, Bouligand J, Francou B, et al. TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. J Clin Endocrinol Metab 2010;95:2287-95
   PubMed Web of Science ®Google Scholar
• Navarro VM, Gottsch ML, Wu M, et al. Regulation of NKB pathways and their roles in the control of Kiss1 neurons in the arcuate nucleus of the male mouse. Endocrinology 2011;152:4265-75
   PubMed Web of Science ®Google Scholar
• Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999;84:3673-80
   PubMed Web of Science ®Google Scholar
• Minegishi T, Nakamura K, Takakura Y, et al. Cloning and sequencing of human LH/hCG receptor cDNA. Biochem Biophys Res Commun 1990;172:1049-54
   PubMed Web of Science ®Google Scholar
• Lin D, Sugawara T, Strauss JFIII, et al. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995;267:1828-31
   PubMed Web of Science ®Google Scholar
• Baker BY, Lin L, Kim CJ, et al. Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab 2006;91:4781-5
   PubMed Web of Science ®Google Scholar
• Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006;27:402-9
   PubMed Web of Science ®Google Scholar
• Gavish M, Bachman I, Shoukrun R, et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev 1999;51:629-50
   PubMed Web of Science ®Google Scholar
• Sinisi AA, Pasquali D, Notaro A, Bellastella A. Sexual differentiation. J Endocrinol Invest 2003;26(3 Suppl):23-8
   PubMedGoogle Scholar
• Gambaryan S, Butt E. Marcus K, et al. cGMP-dependent protein kinase type II regulates basal level of aldosterone production by zonaglomerulosa cells without increasing expression of the steroidogenic acute regulatory protein gene. J Biol Chem 2003;278:29640-8
   PubMed Web of Science ®Google Scholar
• Andric SA, Janjic MM, Stojkov NJ, Kostic TS. Protein kinase G—mediated stimulation of basal Leydig cell steroidogenesis. Am J Physiol Endocrinol Metab 2007;293:1399-408
   PubMed Web of Science ®Google Scholar
• Morelli A, Filippi S, Mancina R, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:2253-63
   PubMed Web of Science ®Google Scholar
• Jarow JP, Chen H, Rosner TW, et al. Assessment of the androgen environment within the human testis: minimally invasive method to obtain intratesticular fluid. J Androl 2001;22:640-5
   PubMed Web of Science ®Google Scholar
• Forti G, Calabresi E, Giannotti P, et al. Measurement of 5-androsten-3beta,17beta-diol in spermatic and peripheral venous blood samples from the same human subjects by a radioimmunoassay method. Horm Res 1978;9:194-200
   PubMedGoogle Scholar
• Coviello AD, Bremner WJ, Matsumoto AM, et al. Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. J Androl 2004;25:931-8
   PubMed Web of Science ®Google Scholar
• Zhang FP, Pakarainen T, Poutanen M, et al. The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis. Proc Natl Acad Sci USA 2003;100:13692-7
   PubMed Web of Science ®Google Scholar
• Singh J, O’Neill C, Handelsman DJ. Induction of spermatogenesis by androgens in gonadotropin-deficient (hpg) mice. Endocrinology 1995;136:5311-21
   PubMed Web of Science ®Google Scholar
• Lerchl A, Sotiriadou S, Behre HM, et al. Restoration of spermatogenesis by follicle-stimulating hormone despite low intratesticular testosterone in photoinhibited hypogonadotropic Djungarian hamsters (Phodopus sungorus). Biol Reprod 1993;49:1108-16
   PubMed Web of Science ®Google Scholar
• Cunningham GR, Huckins C. Persistence of complete spermatogenesis in the presence of low intratesticular concentrations of testosterone. Endocrinology 1979;105:177-86
   PubMed Web of Science ®Google Scholar
• Wang C, Nieschlag E, Swerdloff R, et al. International Society of Andrology (ISA); International Society for the Study of Aging Male (ISSAM); European Association of Urology (EAU); European Academy of Andrology (EAA); American Society of Andrology (ASA). Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009;30:1-9
   PubMedGoogle Scholar
• Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract 2002;8:440-56
   PubMedGoogle Scholar
• Bhasin S, Cunningham GR, Hayes FJ, et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 2013;27:557-79
   PubMed Web of Science ®Google Scholar
• Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother 2014;15:1903-26
   PubMed Web of Science ®Google Scholar
• Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol 2013;9:451-66
   PubMed Web of Science ®Google Scholar
• Yoshida N, Nishizawa N, Matsui H, et al. Development and validation of sensitive sandwich ELISAs for two investigational nonapeptide metastin receptor agonists, TAK-448 and TAK-683. J Pharm Biomed Anal 2012;70:369-77
   PubMed Web of Science ®Google Scholar
• Matsui H, Masaki T, Akinaga Y, et al. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide. Eur J Pharmacol 2014;735:77-85
   PubMed Web of Science ®Google Scholar
• Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab 2005;90:6609-15
   PubMed Web of Science ®Google Scholar
• George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab 2011;96:E1228-36
   PubMed Web of Science ®Google Scholar
• George JT, Veldhuis JD, Tena-Sempere M, et al. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol (Oxf) 2013;79:100-4
   PubMed Web of Science ®Google Scholar
• Asami T, Nishizawa N, Matsui H, et al. Design, synthesis, and biological evaluation of novel investigational nonapeptide KISS1R agonists with testosterone-suppressive activity. J Med Chem 2013;56:8298-307
   PubMed Web of Science ®Google Scholar
• Scott G, Ahmad I, Howard K, et al. Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men. Br J Clin Pharmacol 2013;75:381-91
   PubMed Web of Science ®Google Scholar
• MacLean DB, Matsui H, Suri A, et al. Sustained exposure to the investigational kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies. J Clin Endocrinol Metab 2014;99:E1445-53
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Mannucci E, Maggi M. Factors affecting spermatogenesis upon gonadotropin replacement therapy: a meta-analytic study. Andrology 2014;2(6):794-808
   PubMed Web of Science ®Google Scholar
• Maggi M, Buvat J. Standard operating procedures: pubertas tarda/delayed puberty--male. J Sex Med 2013;10:285-93
   PubMed Web of Science ®Google Scholar
• Büchter D, Behre HM, Kliesch S, Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol 1998;139:298-303
   PubMed Web of Science ®Google Scholar
• Liu L, Banks SM, Barnes KM, Sherins RJ. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1988;67:1140-5
   PubMed Web of Science ®Google Scholar
• Liu L, Chaudhari N, Corle D, Sherins RJ. Comparison of pulsatile subcutaneous gonadotropin-releasing hormone and exogenous gonadotropins in the treatment of men with isolated hypogonadotropic hypogonadism. Fertil Steril 1988;49(2):302-8
   PubMed Web of Science ®Google Scholar
• Oppermann D, Happ J, Mayr WR. Stimulation of spermatogenesis and biological paternity by intranasal (low dose) gonadotropin-releasing hormone (GnRH) in a male with Kallmann’s syndrome: intraindividual comparison of GnRH and gonadotropins for stimulation of spermatogenesis. J Clin Endocrinol Metab 1987;65(5):1060-6
   PubMed Web of Science ®Google Scholar
• Mauk MD, Olson GA, Kastin AJ, Olson RD. Behavioral effects of LH-RH. 1980;4:1-8
   Google Scholar
• Lerner LJ, Holthaus JF, Thompson CR. A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl-ethanol. Endocrinology 1958;63:295-318
   PubMed Web of Science ®Google Scholar
• Kaminetsky J, Hemani ML. Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency. Expert Opin Investig Drugs 2009;18:1947-55
   PubMed Web of Science ®Google Scholar
• Riggs BL, Hartmann LC. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29
   PubMed Web of Science ®Google Scholar
• Comeglio P, Morelli A, Cellai I, et al. Opposite effects of tamoxifen on metabolic syndrome-induced bladder and prostate alterations: a role for GPR30/GPER? Prostate 2014;74:10-28
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Filippi S, Comeglio P, et al. Estrogen mediates metabolic syndrome-induced erectile dysfunction: a study in the rabbit. J Sex Med 2014. [Epub ahead of print]
   Google Scholar
• Duschek EJ, Gooren LJ, Netelenbos C. Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol 2004;150:539-46
   PubMed Web of Science ®Google Scholar
• Farmakiotis D, Farmakis C, Rousso D, et al. The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia. Fertil Steril 2007;88:847-53
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23:808-15
   PubMed Web of Science ®Google Scholar
• Birzniece V, Sata A, Sutanto S, Ho KK. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men. J Clin Endocrinol Metab 2010;95:5443-8
   PubMed Web of Science ®Google Scholar
• Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010;184:1316-21
   PubMed Web of Science ®Google Scholar
• Smith MR, Malkowicz SB, Brawer MK, et al. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol 2011;186:2239-44
   PubMed Web of Science ®Google Scholar
• Filippi S, Luconi M, Granchi S, et al. Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis. Endocrinology 2002;143:4271-80
   PubMed Web of Science ®Google Scholar
• Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res 2006;12:6315s-9s
   PubMed Web of Science ®Google Scholar
• Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005;8:75-83
   PubMed Web of Science ®Google Scholar
• Perdonà S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 2005;6:295-300
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Rubagotti A, Conti G, et al. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol 2010;57:238-45
   PubMed Web of Science ®Google Scholar
• Shabsigh A, Kang Y, Shabsigh R, et al. Clomiphene Citrate Effects on Testosterone/Estrogen Ratio in Male Hypogonadism. J Sex Med 2005;2:716-21
   PubMed Web of Science ®Google Scholar
• Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 1995;80:3546-52
   PubMed Web of Science ®Google Scholar
• Guay AT, Jacobson J, Perez JB, et al. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res 2003;15:156-65
   PubMed Web of Science ®Google Scholar
• Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int 2012;110:573-8
   PubMed Web of Science ®Google Scholar
• Ribeiro RS, Abucham J. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur J Endocrinol 2009;161:163-9
   PubMed Web of Science ®Google Scholar
• Ribeiro RS, Abucham J. Clomiphene fails to revert hypogonadism in most male patients with conventionally treated nonfunctioning pituitary adenomas. Arq Bras Endocrinol Metabol 2011;55:266-71
   PubMed Web of Science ®Google Scholar
• Whitten SJ, Nangia AK, Kolettis PN. Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate. Fertil Steril 2006;86:1664-8
   PubMed Web of Science ®Google Scholar
• Lim VS, Fang VS. Restoration of plasma testosterone levels in uremic men with clomiphene citrate. J Clin Endocrinol Metab 1976;43:1370-7
   PubMed Web of Science ®Google Scholar
• Landefeld CS, Schambelan M, Kaplan SL, Embury SH. Clomiphene-responsive hypogonadism in sickle cell anemia. Ann Intern Med 1983;99:480-3
   PubMed Web of Science ®Google Scholar
• Bjork JT, Varma RR, Borkowf HI. Clomiphene citrate therapy in a patient with Laennec’s cirrhosis. Gastroenterology 1977;72:1308-11
   PubMed Web of Science ®Google Scholar
• Tan RS, Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil Steril 2003;79:202-4
   Web of Science ®Google Scholar
• Ronnberg L, Reinila M, Ylikorkala O. Effects of experimental hyperprolactinemia and clomiphene on pituitary responsiveness to LHRH and TRH in men. Andrologia 1985;17:364-8
   PubMed Web of Science ®Google Scholar
• Moreira AC, Veríssimo JM, Foss MC, et al. Pubertal maturation of the LH stimulatory response to clomiphene citrate in congenital virilizing adrenal hyperplasia. Clin Endocrinol (Oxf) 1982;17:441-7
   PubMed Web of Science ®Google Scholar
• Kulin HE, Grumbach MM, Kaplan SL. Gonadal-hypothalamic interaction in prepubertal and pubertal man: effect of clomiphene citrate on urinary follicle-stimulating hormone and luteinizing hormone and plasma testosterone. Pediatr Res 1972;6:162-71
   PubMed Web of Science ®Google Scholar
• Kamischke A, Nieschlag E. Analysis of medical treatment of male infertility. Hum Reprod 1999;14(Suppl 1):1-23
   PubMedGoogle Scholar
• Vandekerckhove P, Lilford R, Vail A, Hughes E. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000;2:CD000151
   Google Scholar
• Chua ME, Escusa KG, Luna S, et al. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology 2013;1:749-57
   PubMed Web of Science ®Google Scholar
• Hussein A, Ozgok Y, Ross L, Niederberger C. Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. J Androl 2005;26:787-91
   PubMedGoogle Scholar
• Comhaire F. Treatment of oligospermia with tamoxifen. Intern J Fertil 1976;21:232-8
   Google Scholar
• Kadioglu TC. Oral tamoxifen citrate treatment is more effective in normogonadotropic patients who have follicle-stimulating hormone levels within the lower half of normal. Int Urol Nephrol 2009;41:773-6
   PubMed Web of Science ®Google Scholar
• Tsourdi E, Kourtis A, Farmakiotis D, et al. The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. Fertil Steril 2009;91(4 Suppl):1427-30
   PubMed Web of Science ®Google Scholar
• Birzniece V, Sata A, Sutanto S, Ho KK. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men. J Clin Endocrinol Metab 2010;95:5443-8
   PubMed Web of Science ®Google Scholar
• Birzniece V, Sutanto S, Ho KK. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators. J Clin Endocrinol Metab 2012;97:E521-7
   PubMed Web of Science ®Google Scholar
• Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med 2013;10:1628-35
   PubMed Web of Science ®Google Scholar
• Wiehle R, Cunningham GR, Pitteloud N, et al. Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: pharmacodynamics and Pharmacokinetics. BJU Int 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril 2014;102:720-7
   PubMed Web of Science ®Google Scholar
• Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 2008;158:741-7
   PubMed Web of Science ®Google Scholar
• Loves S, de Jong J, van Sorge A, et al. Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. Eur J Endocrinol 2013;169:705-14
   PubMed Web of Science ®Google Scholar
• Kacker R, Conners W, Zade J, Morgentaler A. Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility. J Urol 2014;191:1072-6
   PubMed Web of Science ®Google Scholar
• Liu PY, Wishart SM, Celermajer DS, et al. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 2003;148:55-66
   PubMed Web of Science ®Google Scholar
• Cailleux-Bounacer A, Reznik Y, Cauliez B, et al. Evaluation of endocrine testing of Leydig cell function using extractive and recombinant human chorionic gonadotropin and different doses of recombinant human LH in normal men. Eur J Endocrinol 2008;159:171-8
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Liu PY, Keenan DM, Takahashi PY. Older men exhibit reduced efficacy of and heightened potency downregulation by intravenous pulses of recombinant human LH: a study in 92 healthy men. Am J Physiol Endocrinol Metab 2012;302:E117-22
   PubMed Web of Science ®Google Scholar
• Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2002;87:3125-35
   PubMed Web of Science ®Google Scholar
• Anawalt BD. Approach to male infertility and induction of spermatogenesis. J Clin Endocrinol Metab 2013;98:3532-42
   PubMed Web of Science ®Google Scholar
• Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2002;87:3125-35
   PubMed Web of Science ®Google Scholar
• Liu PY, Wishart SM, Celermajer DS, et al. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 2003;148:55-66
   PubMed Web of Science ®Google Scholar
• Meier C, Liu PY, Ly LP, et al. Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2004;89:3033-41
   PubMed Web of Science ®Google Scholar
• Tsujimura A, Matsumiya K, Takao T, et al. Treatment with human chorionic gonadotropin for PADAM: a preliminary report. Aging Male 2005;8:175-9
   PubMedGoogle Scholar
• Rao CV. An overview of the past, present, and future of nongonadal LH/hCG actions in reproductive biology and medicine. Semin Reprod Med 2001;19:7-17
   PubMed Web of Science ®Google Scholar
• Longcope C. The effect of human chorionic gonadotropin on plasma steroid levels in young and old men. Steroids 1973;21:583-92
   PubMed Web of Science ®Google Scholar
• Corona G, Mondaini N, Ungar A, et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med 2011;8:3418-32
   PubMed Web of Science ®Google Scholar
• Scipioni A, Stefanini S, Santone R, Giorgi M. Immunohistochemical localisation of PDE5 in Leydig and myoid cells of prepubertal and adult rat testis. Histochem Cell Biol 2005;124:401-7
   Google Scholar
• Andric SA, Janjic MM, Stojkov NJ, Kostic TS. Protein kinase G-mediated stimulation of basal Leydig cell steroidogenesis. Am J Physiol Endocrinol Metab 2007;293:E1399-408
   PubMed Web of Science ®Google Scholar
• Saraiva KL, Silva AK, Wanderley MI, et al. Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion. Int J Exp Pathol 2009;90:454-62
   PubMed Web of Science ®Google Scholar
• Janjic MM, Stojkov NJ, Bjelic MM, et al. Transient rise of serum testosterone level after single sildenafil treatment of adult male rats. J Sex Med 2012;9:2534-43
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Filippi S, Comeglio P, et al. Tadalafil effect on metabolic syndrome-associated bladder alterations: an experimental study in a rabbit model. J Sex Med 2014;11:1159-72
   PubMed Web of Science ®Google Scholar
• Morelli A, Comeglio P, Filippi S, et al. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate 2013;73:428-41
   PubMed Web of Science ®Google Scholar
• Carosa E, Martini P, Brandetti F, et al. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol (Oxf) 2004;61:382-6
   PubMed Web of Science ®Google Scholar
• Spitzer M, Bhasin S, Travison TG, et al. Sildenafil increases serum testosterone levels by a direct action on the testes. Andrology 2013;1:913-18
   PubMed Web of Science ®Google Scholar
• Corona G, Isidori AM, Buvat J, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 2014;11:1577-92
   PubMed Web of Science ®Google Scholar
• Mukhin AG, Papadopoulos V, Costa E, Krueger KE. Mitochondrial benzodiazepine receptors regulate steroid biosynthesis. Proc Natl Acad Sci USA 1989;86:9813-16
   PubMed Web of Science ®Google Scholar
• Lacapère JJ, Papadopoulos V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids 2003;68:569-85
   PubMed Web of Science ®Google Scholar
• Tu LN, Morohaku K, Manna PR, et al. Peripheral Benzodiazepine Receptor/Translocator Protein Global Knockout Mice are Viable with no Effects on Steroid Hormone Biosynthesis J Biol Chem. 2014; Epub ahead of print
   Google Scholar
• Morohaku K, Pelton SH, Daugherty DJ, et al. Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. Endocrinology 2014;155:89-97
   PubMed Web of Science ®Google Scholar
• Effects of sexual activity on beard growth in man. Nature 1970;226:869-70
   PubMed Web of Science ®Google Scholar
• Fox CA, Ismail AA, Love DN, et al. Studies on the relationship between plasma testosterone levels and human sexual activity. J Endocrinol 1972;52:51-8
   PubMed Web of Science ®Google Scholar
• Dabbs JMJr, Mohammed S. Male and female salivary testosterone concentrations before and after sexual activity. Physiol Behav 1992;52:195-7
   PubMed Web of Science ®Google Scholar
• LaFerla JJ, Anderson DL, Schalch DS. Psychoendocrine response to sexual arousal in human males. Psychosom Med 1978;40:166-72
   PubMed Web of Science ®Google Scholar
• Raboch J, Starka L. Reported coital activity of men and levels of plasma testosterone. Arch Sex Behav 1973;2:309-15
   PubMed Web of Science ®Google Scholar
• Stearns EL, Winter JS, Faiman C. Effects of coitus on gonadotropin, prolactin and sex steroid levels in man. J Clin Endocrinol Metab 1973;37:687-91
   PubMed Web of Science ®Google Scholar
• Lee PA, Jaffe RB, Midgley ARJr. Lack of alteration of serum gonadotropins in men and women following sexual intercourse. Am J Obstet Gynecol 1974;120:985-7
   PubMed Web of Science ®Google Scholar
• Kraemer HC, Becker HB, Brodie HK, et al. Orgasmic frequency and plasma testosterone levels in normal human males. Arch Sex Behav 1976;5:125-32
   PubMed Web of Science ®Google Scholar
• Brown WA, Monti PM, Corriveau DP. Serum testosterone and sexual activity and interest in men. Arch Sex Behav 1978;7:97-103
   PubMed Web of Science ®Google Scholar
• Jannini EA, Screponi E, Carosa E, et al. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl 1999;22:385-92
   PubMedGoogle Scholar
• Carosa E, Benvenga S, Trimarchi F, et al. Sexual inactivity results in reversible reduction of LH bioavailability. Int J Impot Res 2002;14:93-9
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Filippi S, Morelli A, et al. Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. J Sex Med 2009;6:1270-83
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Lotti F, et al. Impairment of couple relationship in male patients with sexual dysfunction is associated with overt hypogonadism. J Sex Med 2009;6:2591-600
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Filippi S, et al. Erectile dysfunction and central obesity: an Italian perspective. Asian J Androl 2014;16:581-91
   PubMed Web of Science ®Google Scholar
• Corona G, Vignozzi L, Sforza A, Maggi M. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Men Health 2013;31:103-25
   Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1342-0
   Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
   PubMed Web of Science ®Google Scholar
• Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007;334:29912-15
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: a Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Ryan DH, Espeland MA, Foster GD, et al. Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610-28
   PubMedGoogle Scholar
• Pi-Sunyer X, Blackburn G, Brancati FL, et al. Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007;30:1374-83
   PubMed Web of Science ®Google Scholar
• Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004;291:2978-84
   PubMed Web of Science ®Google Scholar
• Gupta BP, Murad MH, Clifton MM, et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2011;171:1797-803
   PubMedGoogle Scholar
• Buchwald H, Williams SE. Bariatric surgery worldwide 2003. Obes Surg 2004;14:1157-64
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013;168:829-43
   PubMed Web of Science ®Google Scholar
• Samavat J, Facchiano E, Lucchese M, et al. Hypogonadism as an additional indication for bariatric surgery in male morbid obesity? Eur J Endocrinol 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Ohlsson C, Nilsson ME, Tivesten A, et al. Comparisons of immunoassay and mass spectrometry measurements of serum estradiol levels and their influence on clinical association studies in men. J Clin Endocrinol Metab 2013;98:E1097-102
   PubMed Web of Science ®Google Scholar
• Håkonsen LB, Thulstrup AM, Aggerholm AS, et al. Does weight loss improve semen quality and reproductive hormones? Results from a cohort of severely obese men. Reprod Health 2011;8:24-31
   PubMed Web of Science ®Google Scholar